Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Seventy-five patients with type IV dyslipidemia were assigned at random to 1 of 2 therapeutic options: group A (control), American Heart Association (AHA) Step II diet and physical activity; and group B, AHA diet, physical activity, and ciprofibrate 100 mg daily for 8 weeks. The lipid profile of all patients was determined at baseline and after therapeutic intervention. RESULTS: Patients in group B (treated with ciprofibrate) compared with group A (control) had significantly higher reductions in total cholesterol (downward arrow 14.2% vs. downward arrow 4.8%; P < 0.02), triglycerides (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), very low density lipoprotein cholesterol (downward arrow 38.0% vs. downward arrow 21.6%; P < 0.007), non- HDL cholesterol (downward arrow 20.5% vs. downward arrow 7.1%; P < 0.007), and total cholesterol/high density cholesterol ratio (downward arrow 25.6% vs. downward arrow 9.4%; P < 0.01). The ciprofibrate group had a significantly higher increase in HDL cholesterol levels compared with the other group (upward arrow 25.0% vs. upward arrow 9.6%, P < 0.02). CONCLUSIONS:
|
Authors | Valmore Bermúdez-Pirela, Aida Souki, Clímaco Cano-Ponce, Fernando Bermúdez-Arias, Edgardo Mengual-Moreno, Elliuz Leal-Gonzalez, Miguel Lemus-Antepaz, Mayela Cabrera de Bravo, Anilsa Amell de Díaz, Nilka Leal de Pirela, Raquel Cano-Peñaloza, Guillermo Puche-Medina, Navlet Arraiz, Nadia Reyna-Villazmil, Freddy Contreras, Zafar H Israili, Manuel Valasco |
Journal | American journal of therapeutics
(Am J Ther)
2007 Mar-Apr
Vol. 14
Issue 2
Pg. 213-20
ISSN: 1075-2765 [Print] United States |
PMID | 17414592
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Cholesterol, VLDL
- Fibric Acids
- Hypolipidemic Agents
- Triglycerides
- Clofibric Acid
- ciprofibrate
|
Topics |
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Cholesterol, VLDL
(blood)
- Clofibric Acid
(analogs & derivatives, pharmacology, therapeutic use)
- Female
- Fibric Acids
- Humans
- Hyperlipoproteinemia Type IV
(drug therapy)
- Hypolipidemic Agents
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Phenotype
- Triglycerides
(blood)
|